LIPAC Oncology

Executive Summary

LIPAC Oncology is a clinical-stage biopharmaceutical company developing precision-targeted, locally delivered cancer therapies based on its proprietary LiPax platform, a neoliposomal formulation of paclitaxel designed for intracavitary administration. The company's initial focus is on urological and gynecological cancers with high unmet need, including non-muscle invasive bladder cancer (NMIBC) and malignant pleural effusion. With a differentiated drug delivery approach that aims to maximize local efficacy while minimizing systemic toxicity, LIPAC is positioned to address significant treatment gaps in localized tumors. The company is currently conducting early-phase clinical trials to establish proof-of-concept and safety in humans.

Upcoming Catalysts (preview)

• Q4 2026Phase 1 Clinical Data Readout for LiPax in NMIBC40% success
• Q2 2027IND Filing for LiPax in Malignant Pleural Effusion50% success
• Q3 2026Series B Financing or Strategic Partnership35% success